Literature DB >> 10724489

Prognostic factors for failure of primary patency within a year of bypass to the foot in patients with diabetes and critical ischaemia.

L Isaksson1, F Lundgren.   

Abstract

OBJECTIVE: To find out whether we could identify prognostic factors for early failure of bypass to the foot in diabetic patients with critical ischaemia.
DESIGN: Retrospective series of consecutive patients.
SETTING: County hospital, Sweden. PATIENTS: 43 diabetic patients who had 48 reconstructions for critical ischaemia between 1988 and 1994.
INTERVENTIONS: 48 elective vein bypass procedures to the feet. MAIN OUTCOME MEASURES: Prognostic factors for primary patency.
RESULTS: Primary and secondary patency rates at one year were 72% (95% confidence interval (CI) 58 to 85) and 83% (95% CI 71 to 95), respectively. Limb salvage and survival rates at one year were 85% (95% CI 74 to 96) and 86% (95% CI 75 to 96), respectively. Vein graft of questionable quality, major wound healing problems, use of the reversed vein technique, and a narrow lumen (< 1.5 mm) of the recipient artery increased the hazard for failed primary patency by 17.3 (p = 0.003), 6.0 (p = 0.02), 4.7 (p = 0.03), and 3.9 (p = 0.05) times, respectively. Short vein bypass (p = 0.70), translocated or composite veins (p = 0.61), major postoperative oedema of the leg (p = 0.46), or questionable quality of the wall of the recipient artery (p = 0.29), however, had no significant independent effect on the primary patency rate.
CONCLUSION: Early primary patency after bypass to the foot in diabetic patients might improve if veins of questionable quality, major wound healing problems, thin reversed veins from the calf, and narrow recipient arteries can be avoided or handled more proficiently than in the present study.

Entities:  

Mesh:

Year:  2000        PMID: 10724489     DOI: 10.1080/110241500750009465

Source DB:  PubMed          Journal:  Eur J Surg        ISSN: 1102-4151


  1 in total

1.  Comprehensive approach to management of critical limb ischemia.

Authors:  Lanfroi Graziani
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.